IASO Bio is a biopharmaceutical company focused on creating innovative cell therapies and biologics for cancer and autoimmune diseases based on our fully human antibodies/binders. Our leading asset is FUCASO, a fully human BCMA-targeting autologous CAR-T. FUCASO demonstrated superior efficacy and safety profile in the pivotal study. It has received NDA approval from China’s NMPA for 4L+ multiple myeloma (MM). We are expanding FUCASO to autoimmune diseases. In a basket IIT study, FUCASO demonstrated promising long-lasting efficacy (functional cure) against multiple autoimmune diseases, including MG, IMNM, NMOSD, CIDP, pSS, and RA. Results of the study have been published in leading scientific journals including EMBO Mol. Med., PNAS and Nature’s STTT. We have received IND approval from the FDA on MG, with more IND applications being prepared. We are also testing FUCASO on additional autoimmune diseases in a new IIT study.